- Home
- ARMP vs IFRX Comparison
ARMP vs IFRX Comparison
Compare ARMP & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- IFRX
- Stock Information
- Founded
- ARMP N/A
- IFRX 2007
- Country
- ARMP United States
- IFRX Germany
- Employees
- ARMP N/A
- IFRX N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ARMP Health Care
- IFRX Health Care
- Exchange
- ARMP Nasdaq
- IFRX Nasdaq
- Market Cap
- ARMP 52.1M
- IFRX 53.5M
- IPO Year
- ARMP N/A
- IFRX 2017
- Fundamental
- Price
- ARMP $2.22
- IFRX $0.88
- Analyst Decision
- ARMP Strong Buy
- IFRX Strong Buy
- Analyst Count
- ARMP 1
- IFRX 4
- Target Price
- ARMP $9.00
- IFRX $7.75
- AVG Volume (30 Days)
- ARMP 18.4K
- IFRX 418.7K
- Earning Date
- ARMP 08-12-2025
- IFRX 08-07-2025
- Dividend Yield
- ARMP N/A
- IFRX N/A
- EPS Growth
- ARMP N/A
- IFRX N/A
- EPS
- ARMP N/A
- IFRX N/A
- Revenue
- ARMP $4,699,000.00
- IFRX $140,242.00
- Revenue This Year
- ARMP $8.43
- IFRX N/A
- Revenue Next Year
- ARMP N/A
- IFRX $6,309.47
- P/E Ratio
- ARMP N/A
- IFRX N/A
- Revenue Growth
- ARMP 14.24
- IFRX 30.90
- 52 Week Low
- ARMP $0.90
- IFRX $0.71
- 52 Week High
- ARMP $3.42
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- ARMP 63.56
- IFRX 46.48
- Support Level
- ARMP $1.93
- IFRX $0.78
- Resistance Level
- ARMP $2.24
- IFRX $1.00
- Average True Range (ATR)
- ARMP 0.16
- IFRX 0.06
- MACD
- ARMP 0.03
- IFRX 0.03
- Stochastic Oscillator
- ARMP 104.55
- IFRX 47.87
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.